By: Rev. Derek McCoy | The Orlando Advocate Heart disease is the longstanding No. 1 killer of Americans, and the leading cause of death among Marylanders. While this silent killer…
By: Selina McKee | PharmaTimes Kidney Cancer UK is calling on the National Institute for Health and Care Excellence to reverse a preliminary decision to bar patients with kidney cancer…
By: Seth Ginsberg | The Detroit News Blaming pharmaceutical companies for high drug prices should be a bipartisan affair. If lawmakers want to hold the responsible culprits accountable, they need…
By: Samuel Louie, MD | The Hill Health insurers searching to lower costs and maximize profits have begun to limit patients’ access to innovative drugs. Most physicians, however, realize that…
By: Jonathan Wilcox | Observer.com ICER and cost control guru Peter Bach are slamming the brakes on innovation No matter what side of the aisle you’re on, we can all…
Inside Health Policy Patient advocacy groups are raising concerns with the proposed use of value-based assessments in the second phase of the controversial Part B drug pay demo, as one…
By: Robert Goldberg | DrugWonks.com After concluding that because myeloma drugs keep people alive longer they cost too much to be cost-effective, ICER through it’s Midwest Comparative Effectiveness Public Advisory…
By: Mario H. Lopez | Fox News Latino When it comes to quality health care, the U.S. Latino population starts out at a serious demographic disadvantage. We are more likely…
ICER has a new target: patients with non-small cell lung cancer. This week, the Institute for Clinical and Economic Review released its latest attack on patients with the publication of…
By: Terry Wilcox | Patients Rising The final ICER Multiple Myeloma report was released on June 9th and came in at breezy 185-pages. Because we know you have a life, we're giving…